Your Complete Policy Management Partner
Everything your healthcare organization needs to confidently maintain accreditation compliance.
Robust document control and workflow management software solution
Simplify & automate policy access, review and approval across your organization
Web-based library of more than 18,000 customizable policy documents
Instantly access up-to-date policies, procedures & forms authored by MCN experts
Automated regulatory notification system of daily email or mobile alerts
Keep current with regulatory changes from more than a dozen federal regulatory bodies, including TJC & NIAHO
What Our Customers are Saying
MCN Healthcare has been indispensable to our accreditation compliance efforts. With Policy Manager, Policy Library and StayAlert!, we have peace of mind that our policies will always be up-to-date and easy to locate.
Beverly McKenzie, Compliance Programs Director, IASIS Healthcare
Helpful MCN Healthcare Resources
The Joint Commission is seeking comment on a set of Patient Blood Management performance measures that build on and update the Joint Commission's previous measure set and are derived exclusively from electronic health records (ePBM). According to TJC, a set of six draft candidate performance measures have been identified under the guidance of a Technical Advisory Panel and include:
- ePBM-01 Pre-op Anemia Screening
- ePBM-02 Pre-op Hemoglobin Level
- ePBM-03 Pre-op Type and Crossmatch, Type and Screen
- ePBM-04 Initial Transfusion Threshold
- ePBM-05 Blood Conservation
- ePBM-06 Outcome of Patient Blood Management
Comments on the candidate measures will be accepted through April 19, 2015. Follow the link below for comment submission instructions. TJC expects that measures will be ready for testing by volunteer hospitals throughout the country during the second and third quarters of 2015.
FDA Drug Safety Communication about Hepatitis C Treatments Containing Sofosbuvir in Combination with Another Direct Acting Antiviral Drug
The U.S. Food and Drug Administration (FDA) is warning that serious slowing of the heart rate can occur when the antiarrhythmic drug amiodarone is taken together with either the hepatitis C drug Harvoni (ledipasvir/sofosbuvir) or with Sovaldi (sofosbuvir) taken in combination with another direct acting antiviral for the treatment of hepatitis C infection. FDA is adding information about symptomatic bradycardia to the Harvoni and Sovaldi labels. The FDA is recommending that health care professionals not prescribe either Harvoni or Sovaldi combined with another direct acting antiviral, such as the investigational drug daclatasvir or Olysio (simeprevir), with amiodarone.
The FDA review of submitted postmarketing adverse event reports found that patients can develop a serious and life-threatening symptomatic bradycardia when either Harvoni or Sovaldi combined with another direct-acting antiviral is taken together with amiodarone. The reports included the death of one patient due to cardiac arrest and three patients requiring placement of a pacemaker to regulate their heart rhythms. The other patients recovered after discontinuing either the hepatitis C drugs or amiodarone, or both (see Data Summary by following the link below for additional inforamtion). The cause of these events could not be determined. The FDA will continue to monitor Harvoni and Sovaldi for risks of serious symptomatic bradycardia and further investigate the reason why the use of amiodarone with these hepatitis C drugs led to the heart-related events.
Health care professionals should not prescribe either Harvoni or Sovaldi combined with another direct-acting antiviral drug with amiodarone. However, in cases where alternative treatment options are unavailable, the FDA recommends heart monitoring in an inpatient hospital setting for the first 48 hours. Subsequently, monitoring in a doctor's office or self-monitoring of the heart rate should be done every day through at least the first two (2) weeks of treatment.
Due to the long half-life of amiodarone, patients discontinuing amiodarone just prior to starting Harvoni, or Sovaldi in combination with another direct-acting antiviral, should also undergo similar cardiac monitoring as outlined above.
Patients taking either Harvoni or Sovaldi combined with another direct-acting antiviral drug with amiodarone should be instructed to seek medical attention right away if they experience signs or symptoms of symptomatic bradycardia.
Read the MedWatch Safety Alert, including a link to the FDA Drug Safety Communication, at the link below.
ISMP Issues Alert about Potential Drug Mix-up between Bloxiverz (neostigmine) injection and Vazculep (phenylephrine) injection
The Institute for Safe Medication Practices (ISMP) is alerting ambulatory surgical centers and anesthesia professionals about the potential for dangerous mix-ups between two relatively new presentations of older medications, neostigmine injection and phenylephrine injection.
ISMP is reporting that in the past three (3) months they have received 8 practitioner reports expressing concern about look-alike packaging of Bloxiverz 10 mg/10 mL (1 mg/mL) and Vazculep 50 mg/5 mL (10 mg/mL). The vials and outer cartons of these two different medications look similar in size, color, and design. Photos of the products and a description of their intended uses are provided on the ISMP Alert a link to which is below.
IMSP is strongly urging healthcare organizations using these products to take immediate steps to safeguard against mix-ups. ISMP recommends consideration of the following actions:
- Store the look-alike medication separately
- Increase awareness about the potential for mix-up with these two medications
- Verify product selection
- Eliminate or limit access
- Dilute prior to injection
Featured Policy Library Manuals
MCN’s Utilities and Equipment Management Policy and procedure Manual is a reference guide that is compliant with Joint Commission, NIAHO and CIHQ standards and CMS regulations. MCN provides easy-to-use policies and procedures that are field tested and proven - you need only to customize them to your healthcare organization. Policies and procedures include Utility Systems Management Plan, Alternative Equipment Maintenance Program, Clinical Alarms, Emergency Power and much more!Read more »
MCN Healthcare’s Administrative Manual for Critical Access Hospitals is specifically designed to assist critical access hospitals meet CMS, TJC and NIAHO standards for CAHs. This manual provides over 275 ready-to-implement policies, procedures and forms in an easy-to-customize Word format, and is designed to demonstrate compliance with CAH regulations. Transplant Safety polices are also included in this manual.Read more »
MCN's NEW Ambulatory Surgical Center/Outpatient Surgery Department Policy and Procedure Manual is cross referenced to TJC standards, AAAHC standards and CMS regulations. Policies and procedures meet AORN and CDC recommendations and guidelines. This comprehensive reference guide has over 290 policies and procedures that are ready to customize to your organization. See also the Administrative Manual for Ambulatory Care Facilities and the Ambulatory Services EOC Manual.Read more »